Seoulin Bioscience (Korea) Performance
| 038070 Stock | KRW 7,340 230.00 3.23% |
Seoulin Bioscience has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Seoulin Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Seoulin Bioscience is expected to be smaller as well. Seoulin Bioscience CoLtd right now has a risk of 5.63%. Please validate Seoulin Bioscience standard deviation, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to decide if Seoulin Bioscience will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Seoulin Bioscience CoLtd are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Seoulin Bioscience may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
| Total Cashflows From Investing Activities | -31.5 B |
Seoulin |
Seoulin Bioscience Relative Risk vs. Return Landscape
If you would invest 721,536 in Seoulin Bioscience CoLtd on October 5, 2024 and sell it today you would earn a total of 12,464 from holding Seoulin Bioscience CoLtd or generate 1.73% return on investment over 90 days. Seoulin Bioscience CoLtd is generating 0.1742% of daily returns and assumes 5.6313% volatility on return distribution over the 90 days horizon. Simply put, 50% of stocks are less volatile than Seoulin, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Seoulin Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seoulin Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seoulin Bioscience CoLtd, and traders can use it to determine the average amount a Seoulin Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0309
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 038070 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.63 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Seoulin Bioscience is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seoulin Bioscience by adding it to a well-diversified portfolio.
Seoulin Bioscience Fundamentals Growth
Seoulin Stock prices reflect investors' perceptions of the future prospects and financial health of Seoulin Bioscience, and Seoulin Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seoulin Stock performance.
| Return On Equity | 10.81 | |||
| Return On Asset | 0.0554 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.1 % | |||
| Current Valuation | 165.44 B | |||
| Shares Outstanding | 7.3 M | |||
| Price To Earning | 42.30 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 80.72 B | |||
| EBITDA | 9.94 B | |||
| Cash And Equivalents | 14.97 B | |||
| Total Debt | 15.22 B | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 7,430 X | |||
| Cash Flow From Operations | 8.92 B | |||
| Total Asset | 136.57 B | |||
| Retained Earnings | 26.92 B | |||
| Current Asset | 33.75 B | |||
| Current Liabilities | 10.11 B | |||
About Seoulin Bioscience Performance
By analyzing Seoulin Bioscience's fundamental ratios, stakeholders can gain valuable insights into Seoulin Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Seoulin Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Seoulin Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company was founded in 1984 and is headquartered in Seongnam, South Korea. SeouLin is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Seoulin Bioscience CoLtd performance evaluation
Checking the ongoing alerts about Seoulin Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seoulin Bioscience CoLtd help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seoulin Bioscience had very high historical volatility over the last 90 days | |
| About 31.0% of the company shares are owned by insiders or employees |
- Analyzing Seoulin Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seoulin Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Seoulin Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seoulin Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seoulin Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seoulin Bioscience's stock. These opinions can provide insight into Seoulin Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Seoulin Stock analysis
When running Seoulin Bioscience's price analysis, check to measure Seoulin Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seoulin Bioscience is operating at the current time. Most of Seoulin Bioscience's value examination focuses on studying past and present price action to predict the probability of Seoulin Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seoulin Bioscience's price. Additionally, you may evaluate how the addition of Seoulin Bioscience to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |